Geno (Genomatica)

Biotech · AI · Biomanufacturing

Acquisition

Again acquires industrial biotech Geno to merge AI with biomanufacturing

The deal fuses computational strain design with physical scale-up, the gap that has stalled many synthetic-biology startups from reaching commercial output.

• Danish technology company Again has acquired San Diego-based industrial biotech Genomatica (Geno), combining AI-driven discovery with industrial-scale manufacturing; financial terms were not disclosed.
• Geno, founded in 2000, develops biotechnology processes that produce chemicals and materials from renewable feedstocks instead of fossil fuels, and had raised over $360M across prior funding rounds.
• Central to the deal is Geno's AI and computational biotechnology platform, plus its patent portfolio and years of experimental R&D data, which Again plans to use to improve modeling and shorten development cycles.
• The combined company will operate through licensing, co-development partnerships, and manufacturing via existing and planned production assets, extending Again from pathway discovery into commercial-scale output.
• The acquisition lands amid a broader consolidation wave in industrial biotech, with Novonesis moving to buy out MicroBioGen's remaining shares to strengthen yeast-strain capabilities the same week.
• Pairing AI-driven molecule design with proven fermentation and scale-up expertise targets the industry's hardest bottleneck: turning lab-scale synthetic biology into manufacturable, commercially viable products.